ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1037

Incidence Of Malignancy In Patients With Rheumatoid Arthritis From a Japanese Large Observational Cohort (NinJa)

Atsushi Hashimoto1, Noriyuki Chiba2, Jinju Nishino3, Toshihiro Matsui4 and Shigeto Tohma5, 1Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 2Department of Rheumatology, Morioka National Hospital, NHO, Iwate, Japan, 3Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, 4Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Kanagawa, Japan, 5Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Epidemiologic methods, Malignancy, methotrexate (MTX) and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose :Patients with rheumatoid arthritis (RA) die mainly of cardiovascular/cerebrovascular diseases, respiratory diseases, infections, or malignancies. In recent years, the ratio of infections and respiratory diseases associated with RA as causes of deaths has been decreasing, whereas that of malignancies increasing. A possible reason is recent changes in RA therapy, namely, elevated dose of methotrexate (MTX) or popularized biologics. Incidence of malignancies varies depending on studies because it is strongly affected by regional or racial differences among cohorts. This study is to disclose incidence and risk of malignancy in Japanese patients with RA.
Methods : Data from RA patientsregistered in a nationwide Japanese cohort database (NinJa: National Database of Rheumatic Diseases by iR-net in Japan) from 2003 to 2011 were used. To adjust difference of population composition and compare the incidence of malignancy between RA patients and general population, standardized incidence rates (SIRs) were calculated. An SIR is a ratio between actually obtained number of malignancies from the cohort and expected number estimated using incidence of age- and sex-matched Japanese population.
Results : In 9 years the cohort comprised of 55003 patient-years (80% females and 18% males) yielded 444 malignancies, which contained 300 (69%) females and 137 (31%) males, including 6 patients with multiple malignancies. Most frequent malignancy was lung cancer (n=71) followed by gastric (n=59) and breast cancer (n=53). SIR for entire malignancies was 0.96 (95% confidence interval 0.87-1.05), which was consistent with that in the general population. SIRs for malignant lymphoma (ML) in both sexes (SIR 4.01) and bladder cancer in females (SIR 2.80) were significantly higher, whereas several malignancies including rectal cancer in both sexes (SIR 0.49), colon cancer in females (SIR 0.89), or liver cancer in both sexes (SIR 0.28) had significantly lower SIRs. Number of patients on MTX therapy and their dose of MTX have been increasing, while annual SIRs for entire malignancies and ML remained steady (figure).
Conclusion : RA patients had no higher incidence for entire malignancies but should be cared for several malignancies including ML.


Disclosure:

A. Hashimoto,
None;

N. Chiba,
None;

J. Nishino,
None;

T. Matsui,
None;

S. Tohma,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-malignancy-in-patients-with-rheumatoid-arthritis-from-a-japanese-large-observational-cohort-ninja/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology